Tulio Alberto Valdez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tulio Alberto Valdez has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Katherine R. Kavanagh
Connecticut Children's, 282 Washington Street 2L, Hartford, Connecticut, 06119, United States
6 shared publications- Stella Yang
Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, Stanford, California 94304, United States
4 shared publications - Oliver Thomas Bruns
Helmholtz Pioneer Campus, Helmholtz Zentrum München, Neuherberg, Germany
3 shared publications - Surya Pratap Singh
Indian Institute of Technology Dharwad
3 shared publications David Zarabanda
Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, USA
2 shared publicationsIram Ahmad
Department of Otolaryngology-Head & Neck Surgery Divisions, Stanford University School of Medicine, Stanford, California 94305, United States
2 shared publications
Latest Publications
- 6 July 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (11) , 5082-5087
Practice Patterns for the Management of Pediatric oSDB : What Is the Current National Landscape?
Objective: As understanding of pediatric obstructive sleep‐disordered breathing (oSDB) evolves, a need remains for clinical consensus within pediatric otolaryngology. We aimed to characterize current national practice patterns in the evaluation and management of pediatric oSDB, including obstructive sleep apnea (OSA), among pediatric otolaryngologists. Methods: We performed a cross‐sectional study of the current 450 ASPO members via an anonymous, confidential, secure, and voluntary online survey. The survey queried practicing pediatric otolaryngologists regarding tonsillectomy techniques, drug‐induced sleep endoscopy (DISE), and multidisciplinary care in the management of pediatric oSDB. Results: Of the 450 current ASPO members invited to participate, 212 (47%) completed the survey. There was wide variability with respect to extracapsular versus intracapsular tonsillectomy techniques for oSDB and OSA indications, with 70% performing intracapsular dissection as part of their practice. A total of 169 respondents (81%) performed DISE, with almost all respondents (99.1%) using a standardized grading scale. Practice patterns did emerge, with more junior surgeons (in practice < 10 years) and those in academic practice being more likely to perform intracapsular tonsillectomy and DISE in clinical practice compared to more senior counterparts and those working in a nonacademic setting ( p < 0.05 for each metric). Multi‐disciplinary care of complex or persistent OSA was more common in academic versus nonacademic settings (64% vs. 26%) ( p < 0.001). Conclusion: Notable variability in pediatric oSDB management across the current national landscape highlights the need to standardize aspects of care, including the role of intracapsular tonsillectomy, pediatric DISE protocols, and multidisciplinary care. Level of Evidence: 5
- 6 July 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (11) , 5082-5087
Practice Patterns for the Management of Pediatric oSDB : What Is the Current National Landscape?
Objective: As understanding of pediatric obstructive sleep‐disordered breathing (oSDB) evolves, a need remains for clinical consensus within pediatric otolaryngology. We aimed to characterize current national practice patterns in the evaluation and management of pediatric oSDB, including obstructive sleep apnea (OSA), among pediatric otolaryngologists. Methods: We performed a cross‐sectional study of the current 450 ASPO members via an anonymous, confidential, secure, and voluntary online survey. The survey queried practicing pediatric otolaryngologists regarding tonsillectomy techniques, drug‐induced sleep endoscopy (DISE), and multidisciplinary care in the management of pediatric oSDB. Results: Of the 450 current ASPO members invited to participate, 212 (47%) completed the survey. There was wide variability with respect to extracapsular versus intracapsular tonsillectomy techniques for oSDB and OSA indications, with 70% performing intracapsular dissection as part of their practice. A total of 169 respondents (81%) performed DISE, with almost all respondents (99.1%) using a standardized grading scale. Practice patterns did emerge, with more junior surgeons (in practice < 10 years) and those in academic practice being more likely to perform intracapsular tonsillectomy and DISE in clinical practice compared to more senior counterparts and those working in a nonacademic setting ( p < 0.05 for each metric). Multi‐disciplinary care of complex or persistent OSA was more common in academic versus nonacademic settings (64% vs. 26%) ( p < 0.001). Conclusion: Notable variability in pediatric oSDB management across the current national landscape highlights the need to standardize aspects of care, including the role of intracapsular tonsillectomy, pediatric DISE protocols, and multidisciplinary care. Level of Evidence: 5
- Open Access
Imaging of Staphylococcus aureus infections and biofilms using a selective covalent probe for the unique serine hydrolase FphE
Staphylococcus aureus is the leading cause of soft tissue infections that can be treated with antibiotics. However, it can also cause significant mortality and morbidity due to systemic infections and infections of surgical implants. Implant infections typically require invasive surgery, and treatment often necessitates removal of the implant because S. aureus biofilms are extremely difficult to eradicate with antibiotic treatment alone. Therefore, there is a significant need for improved diagnostic tools for rapid, non-invasive confirmation of S. aureus infections. We recently developed an activity-based probe containing an oxadiazolone electrophile that selectively labels the S. aureus -specific serine hydrolase, FphE, by covalent binding to its active site serine residue. Here we describe a Cy5-labeled version of the probe, JJ-OX-012, and its characterization as an imaging agent for detecting biofilms both in vitro and in vivo . The probe labeled S. aureus biofilms in vitro , with virtually no background labeling of bacteria that lack FphE expression. Furthermore, we demonstrate that JJ-OX-012 can be used for non-invasive fluorescent imaging as a way to detect S. aureus biofilms in vivo . Overall, these findings support the potential for using covalent probes targeting FphE as imaging agents for rapid detection and diagnosis of staphylococcal infections in vivo .
Open AccessImaging of Staphylococcus aureus infections and biofilms using a selective covalent probe for the unique serine hydrolase FphE
Staphylococcus aureus is the leading cause of soft tissue infections that can be treated with antibiotics. However, it can also cause significant mortality and morbidity due to systemic infections and infections of surgical implants. Implant infections typically require invasive surgery, and treatment often necessitates removal of the implant because S. aureus biofilms are extremely difficult to eradicate with antibiotic treatment alone. Therefore, there is a significant need for improved diagnostic tools for rapid, non-invasive confirmation of S. aureus infections. We recently developed an activity-based probe containing an oxadiazolone electrophile that selectively labels the S. aureus -specific serine hydrolase, FphE, by covalent binding to its active site serine residue. Here we describe a Cy5-labeled version of the probe, JJ-OX-012, and its characterization as an imaging agent for detecting biofilms both in vitro and in vivo . The probe labeled S. aureus biofilms in vitro , with virtually no background labeling of bacteria that lack FphE expression. Furthermore, we demonstrate that JJ-OX-012 can be used for non-invasive fluorescent imaging as a way to detect S. aureus biofilms in vivo . Overall, these findings support the potential for using covalent probes targeting FphE as imaging agents for rapid detection and diagnosis of staphylococcal infections in vivo .
- Open Access
- 7 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Injectable alginate/collagen clindamycin hydrogel for treatment of surgical site infections
The current standard treatment for surgical site infections (SSIs) is marked by prolonged courses of antibiotics, which have limitations due to antibiotic resistance, systemic side effects, and poor patient adherence. We developed a novel injectable alginate/collagen clindamycin hydrogel that rapidly solidifies upon injection and allows for initial burst release followed by sustained release to maintain therapeutic levels. The rheological, morphological, and in-vitro release kinetics of the hydrogel were characterized. Furthermore, with an in-vivo murine SSI model incubated with logarithmic growth phase 1 × 105 CFU Staphylococcus aureus, one time treatment with injectable hydrogel containing 8 mg clindamycin successfully treated SSI comparable to a cumulative systemic antibiotic dose of 42 mg clindamycin. In an implant SSI model, two-time treatment with the injectable clindamycin antibiotic (16 mg total) successfully suppressed infection and prevented recalcitrant infection. To date, no group has developed a clindamycin encapsulated injectable alginate/collagen hydrogel for the treatment of infection. This tunable hydrogel may serve as an effective delivery vehicle for clinical applications in treating SSIs compared to conventionally available treatments.
- 7 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessInjectable alginate/collagen clindamycin hydrogel for treatment of surgical site infections
The current standard treatment for surgical site infections (SSIs) is marked by prolonged courses of antibiotics, which have limitations due to antibiotic resistance, systemic side effects, and poor patient adherence. We developed a novel injectable alginate/collagen clindamycin hydrogel that rapidly solidifies upon injection and allows for initial burst release followed by sustained release to maintain therapeutic levels. The rheological, morphological, and in-vitro release kinetics of the hydrogel were characterized. Furthermore, with an in-vivo murine SSI model incubated with logarithmic growth phase 1 × 105 CFU Staphylococcus aureus, one time treatment with injectable hydrogel containing 8 mg clindamycin successfully treated SSI comparable to a cumulative systemic antibiotic dose of 42 mg clindamycin. In an implant SSI model, two-time treatment with the injectable clindamycin antibiotic (16 mg total) successfully suppressed infection and prevented recalcitrant infection. To date, no group has developed a clindamycin encapsulated injectable alginate/collagen hydrogel for the treatment of infection. This tunable hydrogel may serve as an effective delivery vehicle for clinical applications in treating SSIs compared to conventionally available treatments.
- Open Access
Intraoperative nerve imaging with sodium fluorescein
Nerve damage during surgery is a common and serious complication, often leading to chronic pain, functional impairments, and diminished quality of life. However, existing methods for intraoperative nerve identification remain insufficient, especially for detecting small or hidden nerve branches. Here we present a new application of a clinically approved fluorescent agent, sodium fluorescein, to enhance nerve visualization during surgery. Utilizing both clinical and customized imaging systems, fluorescein remarkably improved nerve contrast, revealing structures undetectable with white light, including small branches embedded within tissues. With its established safety profile, low cost, and immediate clinical applicability, sodium fluorescein offers the potential to revolutionize surgical practice by minimizing nerve injuries and improving patient outcomes. Clinical Trial Registration: NCT06054178 . Graphical
Open AccessIntraoperative nerve imaging with sodium fluorescein
Nerve damage during surgery is a common and serious complication, often leading to chronic pain, functional impairments, and diminished quality of life. However, existing methods for intraoperative nerve identification remain insufficient, especially for detecting small or hidden nerve branches. Here we present a new application of a clinically approved fluorescent agent, sodium fluorescein, to enhance nerve visualization during surgery. Utilizing both clinical and customized imaging systems, fluorescein remarkably improved nerve contrast, revealing structures undetectable with white light, including small branches embedded within tissues. With its established safety profile, low cost, and immediate clinical applicability, sodium fluorescein offers the potential to revolutionize surgical practice by minimizing nerve injuries and improving patient outcomes. Clinical Trial Registration: NCT06054178 . Graphical
- 5 October 2024
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 186, 112122
Advancing neonatal hearing screening in Latin America: Insights from pediatric otolaryngologists
- 5 October 2024
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 186, 112122
Advancing neonatal hearing screening in Latin America: Insights from pediatric otolaryngologists
- 20 July 2024
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 57 (5) , 853-862
Artificial Intelligence and Pediatric Otolaryngology
- 20 July 2024
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 57 (5) , 853-862
Artificial Intelligence and Pediatric Otolaryngology
- Open Access
- 23 January 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (2) , 104
Label-Free Optical Technologies for Middle-Ear Diseases
Medical applications of optical technology have increased tremendously in recent decades. Label-free techniques have the unique advantage of investigating biological samples in vivo without introducing exogenous agents. This is especially beneficial for a rapid clinical translation as it reduces the need for toxicity studies and regulatory approval for exogenous labels. Emerging applications have utilized label-free optical technology for screening, diagnosis, and surgical guidance. Advancements in detection technology and rapid improvements in artificial intelligence have expedited the clinical implementation of some optical technologies. Among numerous biomedical application areas, middle-ear disease is a unique space where label-free technology has great potential. The middle ear has a unique anatomical location that can be accessed through a dark channel, the external auditory canal; it can be sampled through a tympanic membrane of approximately 100 microns in thickness. The tympanic membrane is the only membrane in the body that is surrounded by air on both sides, under normal conditions. Despite these favorable characteristics, current examination modalities for middle-ear space utilize century-old technology such as white-light otoscopy. This paper reviews existing label-free imaging technologies and their current progress in visualizing middle-ear diseases. We discuss potential opportunities, barriers, and practical considerations when transitioning label-free technology to clinical applications.
- 23 January 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (2) , 104
Open AccessLabel-Free Optical Technologies for Middle-Ear Diseases
Medical applications of optical technology have increased tremendously in recent decades. Label-free techniques have the unique advantage of investigating biological samples in vivo without introducing exogenous agents. This is especially beneficial for a rapid clinical translation as it reduces the need for toxicity studies and regulatory approval for exogenous labels. Emerging applications have utilized label-free optical technology for screening, diagnosis, and surgical guidance. Advancements in detection technology and rapid improvements in artificial intelligence have expedited the clinical implementation of some optical technologies. Among numerous biomedical application areas, middle-ear disease is a unique space where label-free technology has great potential. The middle ear has a unique anatomical location that can be accessed through a dark channel, the external auditory canal; it can be sampled through a tympanic membrane of approximately 100 microns in thickness. The tympanic membrane is the only membrane in the body that is surrounded by air on both sides, under normal conditions. Despite these favorable characteristics, current examination modalities for middle-ear space utilize century-old technology such as white-light otoscopy. This paper reviews existing label-free imaging technologies and their current progress in visualizing middle-ear diseases. We discuss potential opportunities, barriers, and practical considerations when transitioning label-free technology to clinical applications.
- 6 September 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (3) , 1023-1031
Cough Sounds in Screening and Diagnostics: A Scoping Review
Objective: The aim of the study was to examine applications of cough sounds towards screening tools and diagnostics in the biomedical and engineering literature, with particular focus on disease types, acoustic data collection protocols, data processing and analytics, accuracy, and limitations.Data Sources: PubMed, EMBASE, Web of Science, Scopus, Cochrane Library, IEEE Xplore, Engineering Village, and ACM Digital Library were searched from inception to August 2021.Review Methods: A scoping review was conducted on screening and diagnostic uses of cough sounds in adults, children, and animals, in English peer‐reviewed and gray literature of any design.Results: From a total of 438 abstracts screened, 108 articles met inclusion criteria. Human studies were most common (77.8%); the majority focused on adults (57.3%). Single‐modality acoustic data collection was most common (71.2%), with few multimodal studies, including plethysmography (15.7%) and clinico‐demographic data (7.4%). Data analytics methods were highly variable, with 61.1% using machine learning, the majority of which (78.8%) were published after 2010. Studies commonly focused on cough detection (41.7%) and screening of COVID‐19 (11.1%); among pediatric studies, the most common focus was diagnosis of asthma (52.6%).Conclusion: Though the use of cough sounds in diagnostics is not new, academic interest has accelerated in the past decade. Cough sound offers the possibility of an accessible, noninvasive, and low‐cost disease biomarker, particularly in the era of rapid development of machine learning capabilities in combination with the ubiquity of cellular technology with high‐quality recording capability. However, most cough sound literature hinges on nonstandardized data collection protocols and small, nondiverse, single‐modality datasets, with limited external validity.Laryngoscope, 134:1023–1031, 2024
- 6 September 2023
- Published by Wiley in The Laryngoscope
- Vol. 134 (3) , 1023-1031
Cough Sounds in Screening and Diagnostics: A Scoping Review
Objective: The aim of the study was to examine applications of cough sounds towards screening tools and diagnostics in the biomedical and engineering literature, with particular focus on disease types, acoustic data collection protocols, data processing and analytics, accuracy, and limitations.Data Sources: PubMed, EMBASE, Web of Science, Scopus, Cochrane Library, IEEE Xplore, Engineering Village, and ACM Digital Library were searched from inception to August 2021.Review Methods: A scoping review was conducted on screening and diagnostic uses of cough sounds in adults, children, and animals, in English peer‐reviewed and gray literature of any design.Results: From a total of 438 abstracts screened, 108 articles met inclusion criteria. Human studies were most common (77.8%); the majority focused on adults (57.3%). Single‐modality acoustic data collection was most common (71.2%), with few multimodal studies, including plethysmography (15.7%) and clinico‐demographic data (7.4%). Data analytics methods were highly variable, with 61.1% using machine learning, the majority of which (78.8%) were published after 2010. Studies commonly focused on cough detection (41.7%) and screening of COVID‐19 (11.1%); among pediatric studies, the most common focus was diagnosis of asthma (52.6%).Conclusion: Though the use of cough sounds in diagnostics is not new, academic interest has accelerated in the past decade. Cough sound offers the possibility of an accessible, noninvasive, and low‐cost disease biomarker, particularly in the era of rapid development of machine learning capabilities in combination with the ubiquity of cellular technology with high‐quality recording capability. However, most cough sound literature hinges on nonstandardized data collection protocols and small, nondiverse, single‐modality datasets, with limited external validity.Laryngoscope, 134:1023–1031, 2024
- Open Access
Novel Imaging Guidance for Cholesteatoma Surgery using Tissue Autofluorescence
Significance: Cholesteatoma is an expansile destructive lesion of the middle ear and mastoid, which can result in significant complications by eroding adjacent bony structures. Currently, there is an inability to accurately distinguish cholesteatoma tissue margins from middle ear mucosa tissue, causing a high recidivism rate. Accurately differentiating cholesteatoma and mucosa will enable a more complete removal of the tissue. Aim: Develop an imaging system to enhance the visibility of cholesteatoma tissue and margins during surgery. Approach: Cholesteatoma and mucosa tissue samples were excised from the inner ear of patients and illuminated with 405, 450, and 520 nm narrowband lights. Measurements were made with a spectroradiometer equipped with a series of different longpass filters. Images were obtained using a red-green-blue (RGB) digital camera equipped with a long pass filter to block reflected light. Results: Cholesteatoma tissue fluoresced under 405 and 450 nm illumination. Middle ear mucosa tissue did not fluoresce under the same illumination and measurement conditions. All measurements were negligible under 520 nm illumination conditions. All spectroradiometric measurements of cholesteatoma tissue fluorescence can be predicted by a linear combination of emissions from keratin and flavin adenine dinucleotide (FAD). We built a prototype of a fluorescence imaging system using a 495 nm longpass filter in combination with an RGB camera. The system was used to capture calibrated digital camera images of cholesteatoma and mucosa tissue samples. The results confirm that cholesteatoma emits light when it is illuminated with 405 and 450 nm, whereas mucosa tissue does not. Conclusions: We prototyped an imaging system that is capable of measuring cholesteatoma tissue autofluorescence.
Open AccessNovel Imaging Guidance for Cholesteatoma Surgery using Tissue Autofluorescence
Significance: Cholesteatoma is an expansile destructive lesion of the middle ear and mastoid, which can result in significant complications by eroding adjacent bony structures. Currently, there is an inability to accurately distinguish cholesteatoma tissue margins from middle ear mucosa tissue, causing a high recidivism rate. Accurately differentiating cholesteatoma and mucosa will enable a more complete removal of the tissue. Aim: Develop an imaging system to enhance the visibility of cholesteatoma tissue and margins during surgery. Approach: Cholesteatoma and mucosa tissue samples were excised from the inner ear of patients and illuminated with 405, 450, and 520 nm narrowband lights. Measurements were made with a spectroradiometer equipped with a series of different longpass filters. Images were obtained using a red-green-blue (RGB) digital camera equipped with a long pass filter to block reflected light. Results: Cholesteatoma tissue fluoresced under 405 and 450 nm illumination. Middle ear mucosa tissue did not fluoresce under the same illumination and measurement conditions. All measurements were negligible under 520 nm illumination conditions. All spectroradiometric measurements of cholesteatoma tissue fluorescence can be predicted by a linear combination of emissions from keratin and flavin adenine dinucleotide (FAD). We built a prototype of a fluorescence imaging system using a 495 nm longpass filter in combination with an RGB camera. The system was used to capture calibrated digital camera images of cholesteatoma and mucosa tissue samples. The results confirm that cholesteatoma emits light when it is illuminated with 405 and 450 nm, whereas mucosa tissue does not. Conclusions: We prototyped an imaging system that is capable of measuring cholesteatoma tissue autofluorescence.
- Open Access
- 1 June 2023
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 28 (06) , 066003-14
Imaging guidance for cholesteatoma surgery using tissue autofluorescence
Cholesteatoma is a proliferative mass of keratinized epithelium overlying a fibrous stroma that occurs in the middle ear and mastoid cavity.1 The term “cholesteatoma” was first used in 1838 by Johannes Müller (1801 to 1858), a German scientist and author most notable for his work in psychology and pathology,2 based on his belief that the mass was composed mostly of cholesterine.3 Despite the term cholesteatoma being a misnomer (as this benign mass contains neither cholesterine nor fat), it is still the most commonly used term to refer to these masses. It is widely recognized that cholesteatomas are divided into two categories: congenital and acquired. Cholesteatomas are considered congenital when it presents in the absence of prior surgery or perforation and usually occur in the pediatric population.4,5 These lesions are often asymptomatic and are detected either during routine pediatric visits or when the disease is grossly advanced. When cholesteatoma cases become symptomatic, common manifestations include: otorrhea,6 otalgia,7 and hearing loss.8 Acquired cholesteatoma occurs at an annual rate of about 9 to 14 cases per 100,000 adults, and 3 to 17 cases per 100,000 children. Furthermore, there is a greater amount of acquired cholesteatoma, roughly 70% to 96% of all cases.9 – 11
- 1 June 2023
- Published by SPIE-Intl Soc Optical Eng in Journal of Biomedical Optics
- Vol. 28 (06) , 066003-14
Open AccessImaging guidance for cholesteatoma surgery using tissue autofluorescence
Cholesteatoma is a proliferative mass of keratinized epithelium overlying a fibrous stroma that occurs in the middle ear and mastoid cavity.1 The term “cholesteatoma” was first used in 1838 by Johannes Müller (1801 to 1858), a German scientist and author most notable for his work in psychology and pathology,2 based on his belief that the mass was composed mostly of cholesterine.3 Despite the term cholesteatoma being a misnomer (as this benign mass contains neither cholesterine nor fat), it is still the most commonly used term to refer to these masses. It is widely recognized that cholesteatomas are divided into two categories: congenital and acquired. Cholesteatomas are considered congenital when it presents in the absence of prior surgery or perforation and usually occur in the pediatric population.4,5 These lesions are often asymptomatic and are detected either during routine pediatric visits or when the disease is grossly advanced. When cholesteatoma cases become symptomatic, common manifestations include: otorrhea,6 otalgia,7 and hearing loss.8 Acquired cholesteatoma occurs at an annual rate of about 9 to 14 cases per 100,000 adults, and 3 to 17 cases per 100,000 children. Furthermore, there is a greater amount of acquired cholesteatoma, roughly 70% to 96% of all cases.9 – 11